Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onyx BiotecNSE:ONYX 14 EV-to-EBITDA is 22.75 as of Aug. 31, 2026, which is 223% above its 10-year median of 7.04. GuruFocus rates NSE:ONYX with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 520 Medical Devices & Instruments companies, Onyx Biotec ranks worse than 70.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Onyx Biotec's enterprise value is ₹873.8 Mil.
Onyx Biotec's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38.4 Mil. Therefore, Onyx Biotec's EV-to-EBITDA for today is 22.75.
The historical rank and industry rank for Onyx Biotec's EV-to-EBITDA or its related term are showing as below:
NSE:ONYX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.27 Med: 7.04 Max: 24.01
Current: 22.75
During the past 5 years, the highest EV-to-EBITDA of Onyx Biotec was 24.01. The lowest was 4.27. And the median was 7.04.
NSE:ONYX's EV-to-EBITDA is ranked worse than 70.38% of 520
companies
in the Medical Devices & Instruments industry
Industry Median: 14.68
vs NSE:ONYX: 22.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Onyx Biotec's PE Ratio (TTM) for today is calculated as:
Onyx Biotec's share price for today is ₹42.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Onyx Biotec's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.120.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Onyx Biotec's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONYX vs ISRG, BDX, RMD: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Onyx Biotec's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Biotec EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Onyx Biotec's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Onyx Biotec's EV-to-EBITDA falls into.
Onyx Biotec's current Enterprise Value is ₹873.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Onyx Biotec's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹38.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onyx Biotec (NSE:ONYX) has a EV-to-EBITDA of 22.75 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Onyx Biotec. This is 223% above median its historical median of 7.04. Over the past decade, Onyx Biotec's EV-to-EBITDA has ranged from 4.27 to 24.01. According to the industry distribution chart, Onyx Biotec ranks #366 out of 520 companies in the Medical Devices & Instruments industry, placing it in the top 70.4%.
Is Onyx Biotec's EV-to-EBITDA too high?
Onyx Biotec's current EV-to-EBITDA of 22.75 is 223% above median its 10-year median of 7.04. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 24.01. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.68. Onyx Biotec's value of 22.75 is 55% above this industry median. Based on the distribution chart, Onyx Biotec ranks #366 out of 520 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Onyx Biotec has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Onyx Biotec's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Onyx Biotec ranks #366 out of 520 companies for EV-to-EBITDA. This places Onyx Biotec in the lower half of its industry. The industry median EV-to-EBITDA is 14.68. Onyx Biotec's value of 22.75 is 55% above this benchmark. Historically, Onyx Biotec's own EV-to-EBITDA has ranged from 4.27 to 24.01 over the past decade. While the company's 10-year median is 7.04 vs. the industry median of 14.68, Onyx Biotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.68, based on 520 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Biotec's current EV-to-EBITDA of 22.75 is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Onyx Biotec. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Biotec's current EV-to-EBITDA is 22.75, which is 223% above median its own 10-year median of 7.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Biotec stock overvalued right now?
Onyx Biotec (NSE:ONYX) has a current EV-to-EBITDA of 22.75. The current EV-to-EBITDA is 22.75, which is 223% above median its 10-year median of 7.04 and 55% above the Medical Devices & Instruments industry median of 14.68. Onyx Biotec's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Onyx Biotec (NSE:ONYX), the current EV-to-EBITDA is 22.75 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onyx Biotec Ltd is engaged in healthcare segment and offering Sterile Pharmaceutical products ,and acts as a pharmaceutical contract manufacturer. It offering products such as Sterile Water for Injections, Dry Powder Injections and Dry Syrup for India and overseas. Key revenue is generated from Sterile Water for Injections .
14GF Score
Get the complete analysis for NSE:ONYX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONYX has been successfully added to your 
